Search Results for: 43

Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results

— Preliminary Agreement Reached with FDA on Proposed Phase 3 Clinical Trial Synopsis for SYN-004 (ribaxamase) — — Conference Call Today, May 8, 2018, at 4:30 p.m. (EDT) — ROCKVILLE, Md., May 8, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore

Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results Read More »

Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results

— Company Provides Update on Late-stage Microbiome-focused Product Candidates — — Conference Call Today, February 22, 2018, at 8:30 a.m. (EST) — ROCKVILLE, Md., Feb. 22, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a

Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results Read More »

Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference

ROCKVILLE, Md., Jan. 2, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steven Shallcross, Interim CEO & CFO, is scheduled to present at the Biotech Showcase™ 2018 Conference next week in San Francisco, as

Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference Read More »

Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results

— Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Held Initial Type-B Multidisciplinary Meeting with FDA to Discuss Late-Stage Clinical Advancement for SYN-004 (ribaxamase) — — Conference Call Today, November 1, 2017, at 4:30 p.m. EDT — ROCKVILLE, Md., Nov. 1, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage

Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results Read More »

Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results

— SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI — — Three Ribaxamase Presentations to be Included at Infectious Disease Week™ (ID Week) 2017 — — Conference Call Today, August 3, 2017, at 8:30 a.m. EDT — ROCKVILLE, Md., Aug. 3, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage

Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results Read More »

Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results

— Results from Phase 2b Proof-of-Concept Study Exploratory Endpoints Demonstrate Ribaxamase Protects and Preserves Gut Microbiome from Ceftriaxone-mediated Dysbiosis — — Two Ribaxamase and Two SYN-010 Presentations to be Included at Digestive Disease Week (DDW 2017) — — Conference Call Today, May 4, 2017, at 4:30 p.m. (EDT) — ROCKVILLE, Md., May 4, 2017 /PRNewswire/

Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results Read More »

Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results

— Company Highlights Clinical Successes of Late-stage Microbiome-focused Programs, Plans for Phase 3 Development — — Conference Call Today, March 2, 2017, at 4:30 p.m. (EST) — ROCKVILLE, Md., March 2, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health

Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results Read More »

Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants

ROCKVILLE, Md., Nov. 15, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock and warrants to purchase 50,000,000 shares of its common stock at a price to the public

Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants Read More »

Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results

— Completed Enrollment of Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection (CDI), Antibiotic-Associated Diarrhea (AAD) and the Emergence of Antibiotic-Resistant Organisms — — Awarded Research Contract from Centers for Disease Control and Prevention to Determine SYN-004’s (ribaxamase) Ability to Prevent Antibiotic-Resistance in the Gut Microbiome — — Conference Call Today,

Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results Read More »